BioPhenoMA develops an AI-powered platform for detecting ultra-trace proteins that helps accelerate new drug discovery phases.
BioPhenoMA has raised $1.2M in total funding. The most recent round was Seed. The last funding was announced in November 2024.
BioPhenoMA's investors include JMTC Capital, WASEDA University Ventures.
BioPhenoMA is headquartered in Tokyo, Japan.
BioPhenoMA develops an AI-powered platform for detecting ultra-trace proteins that helps accelerate new drug discovery phases.
BioPhenoMA is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioPhenoMA — Funding & Investors." VCBacked, November 7, 2024, https://www.vcbacked.co/company/biophenoma. Accessed August 14, 2026.
VCBacked. (2024). BioPhenoMA — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/biophenoma
{{cite web |title=BioPhenoMA — Funding & Investors |url=https://www.vcbacked.co/company/biophenoma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated